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IMPORTANCE Previous studies assessing the effect of metformin on glycemic control in
adolescents with type 1 diabetes have produced inconclusive results.
OBJECTIVE To assess the efficacy and safety of metformin as an adjunct to insulin in treating
overweight adolescents with type 1 diabetes.
DESIGN, SETTING, AND PARTICIPANTS Multicenter (26 pediatric endocrinology clinics),
double-blind, placebo-controlled randomized clinical trial involving 140 adolescents aged 12.1
to 19.6 years (mean [SD] 15.3 [1.7] years) with mean type 1 diabetes duration 7.0 (3.3) years,
mean bodymass index (BMI) 94th (4) percentile, mean total daily insulin 1.1 (0.2) U/kg, and
mean HbA1c 8.8% (0.7%).
INTERVENTIONS Randomization to receive metformin (n = 71) (2000mg/d) or placebo
(n = 69).
MAIN OUTCOMES ANDMEASURES Primary outcomewas change in HbA1c from baseline to 26
weeks adjusted for baseline HbA1c. Secondary outcomes included change in blinded
continuous glucosemonitor indices, total daily insulin, BMI, waist circumference, body
composition, blood pressure, and lipids.
RESULTS Between October 2013 and February 2014, 140 participants were enrolled. Baseline
HbA1c was 8.8% in each group. At 13-week follow-up, reduction in HbA1c was greater with
metformin (−0.2%) than placebo (0.1%; mean difference, −0.3% [95% CI, −0.6% to 0.0%];
P = .02). However, this differential effect was not sustained at 26-week follow upwhenmean
change in HbA1c from baseline was 0.2% in each group (mean difference, 0% [95% CI, −0.3%
to 0.3%]; P = .92). At 26-week follow-up, total daily insulin per kg of body weight was
reduced by at least 25% from baseline among 23% (16) of participants in themetformin
group vs 1% (1) of participants in the placebo group (mean difference, 21% [95% CI, 11% to
32%]; P = .003), and 24% (17) of participants in themetformin group and 7% (5) of
participants in the placebo group had a reduction in BMI z score of 10% or greater from
baseline to 26 weeks (mean difference, 17% [95% CI, 5% to 29%]; P = .01). Gastrointestinal
adverse events were reported bymore participants in themetformin group than in the
placebo group (mean difference, 36% [95% CI, 19% to 51%]; P < .001).
CONCLUSIONS AND RELEVANCE Among overweight adolescents with type 1 diabetes, the
addition of metformin to insulin did not improve glycemic control after 6months. Of multiple
secondary end points, findings favoredmetformin only for insulin dose andmeasures of
adiposity; conversely, use of metformin resulted in an increased risk for gastrointestinal
adverse events. These results do not support prescribing metformin to overweight
adolescents with type 1 diabetes to improve glycemic control.
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D espite the traditional phenotype of individuals withtype 1 diabetes as having normal weight or beingunderweight, observational studies show, similar to
the general population, increasing numbers of overweight
and obese individuals with type 1 diabetes.1 Recent data from
the T1D (type 1 diabetes) Exchange Clinic registry indicated
that in more than 11 000 US children and adolescents with
type 1 diabetes, 24% were overweight and an additional
15% were obese.2 For youth with type 1 diabetes, being over-
weight or obese potentially has serious metabolic conse-
quences, especially during adolescence. Among these indi-
viduals, the high doses of insulin required to overcome the
insulin resistance of obesity and puberty contribute to diffi-
culties in glycemic control3-7 and may promote further
weight gain. In addition, among adolescents with type 1 dia-
betes, insulin resistance has been associated with increases
in cardiovascular risk factors.8
Metformin is an oral glucose-lowering agent commonly
used in treating type 2 diabetes. It improves glycemia in type
2 diabetes by several mechanisms including lowering
hepatic glucose output and increasing peripheral uptake of
glucose, especially in the muscle.9 A meta-analysis10 showed
that metformin treatment was associated with significantly
low insulin doses but had no effect on hemoglobin A1c
(HbA1c) levels in adults with type 1 diabetes. However, stud-
ies in adolescents have been small, of short duration, or
used nonstandard doses of metformin and have produced
inconclusive results.11-14 We designed a 6-month, multi-
center, placebo-controlled, randomized trial to assess the
effect of the addition of metformin, 2000 mg per day, to
basal-bolus insulin treatment in overweight and obese ado-
lescents with type 1 diabetes.
Methods
The trial was conducted at 26 clinical sites of the T1D
Exchange Clinic Network. The protocol and Health Insur-
ance Portability and Accountability Act (HIPAA)–compliant
informed consent forms were approved by local institutional
review boards. Written informed consent was obtained from
participants aged 18 years and older or from a parent or
guardian for younger participants who also assented. Study
oversight was provided by an independent data and safety
monitoring committee. The complete study protocol and
statistical analysis plan are available in Supplement 1.
Study Participants
Major inclusion criteria included presumed autoimmune
type 1 diabetes (as indicated by age of diagnosis <10 years or
documented positive diabetes-related autoantibodies) for at
least 1 year treated with either an insulin pump or at least 3
daily injections of insulin, age of 12 to less than 20 years,
HbA1c level of 7.5% to 9.9% from point-of-care measurement
or local laboratory, body mass index (BMI, calculated using
reference tables from the Centers for Disease Control and Pre-
vention [CDC])15 in the 85th percentile or greater for age and
sex, total daily insulin dose of at least 0.8 units per kg per
day, and frequency of self-monitoring of blood glucose at
least 3 times per day (eTable 1 in Supplement 2 for a complete
listing of eligibility and exclusion criteria). Race/ethnicity and
socioeconomic status were determined from clinician report
in order to characterize the study cohort.
Treatment
Following verification of eligibility from data entered on the
studywebsite, each participantwas assigned randomlyusing
a computer-generated sequence to either metformin or pla-
cebo with equal probability using a permuted block design
stratified by screening HbA1c (7.5%-8.9% and 9.0%-9.9%). A
central pharmacy compounded the placebo to match the
500mgmetformin tablets.
The daily dose of study drug was increased over 4 weeks
as follows: 1 tablet in the evening for 7 days, 1 tablet twice
daily for 7 days, 1 tablet in the morning and 2 tablets at night
for 7 days, and then 2 tablets in the morning and 2 tablets at
night daily (2000mg) for the remainder of the 26-week treat-
ment period. A dose of 2000 mg of metformin was used
without regard to each participant’s weight because weight-
based dosing is not common practice for metformin therapy,
and a daily dose of 2000 mg is the standard dose used in
managing type 2 diabetes in adolescent patients. Study drug
dosage could be titrated at a slower rate and/or adjusted due
to adverse effects per investigator discretion. Clinician judg-
ment was used to adjust insulin doses. Pill counts of bottles
returned by study participants were used to assess the
amount of study drug taken.
Follow-up Visits
During the first 4 weeks after randomization, participants
received weekly phone calls about adjustment of the study
drug and their insulin dosages and assessment for adverse
events. Office visits were conducted after 6, 13, and 26
weeks, and an additional phone contact was made at 20
weeks. The study drug was discontinued following the
26-week wearing of a continuous glucose monitor and a
final visit was conducted 4 to 6 weeks later (eFigure 1 in
Supplement 2).
Study Procedures and Assessments
At baseline, 13 weeks, and 26 weeks, each participant’s
height, weight, blood pressure, and waist circumference
were measured; fasting blood was drawn for measurement
at a central laboratory (Northwest Lipid Research Laborato-
ries, University of Washington, Seattle) of HbA1c (automated
glycohemoglobin analyzer HLC-723G8, Tosoh Bioscience),
serum lipids (total cholesterol, high-density lipoprotein
cholesterol [HDL-C], low-density lipoprotein cholesterol
[LDL-C], triglycerides), liver enzymes (alanine aminotrans-
ferase and aspartate aminotransferase), creatinine, and
C-peptide. Each participant was asked to wear a blinded
continuous glucose monitor sensor (iPro2 digital recorder
with Enlite sensor, Medtronic Diabetes) for 3 to 7 days at
baseline, 13 weeks, and 26 weeks. Tanner staging was per-
formed at randomization and again at 26 weeks if a partici-
pant had not developed to stage 5 (adult quantity and type
Research Original Investigation Metformin for AdolescentsWith Type 1 Diabetes
2242 JAMA December 1, 2015 Volume 314, Number 21 (Reprinted) jama.com
Downloaded From: http://jama.jamanetwork.com/ by a Indiana University School of Medicine User  on 06/08/2016
Copyright 2015 American Medical Association. All rights reserved.
of pubic hair for both sexes, adult breasts for adolescent
girls, and adult genitalia for adolescent boys) at randomiza-
tion; dual-energy x-ray absorptiometry (DXA) scans
were performed to assess body composition. Participants
with detectable C-peptide (≥0.51 ng/mL; to convert to
nmol/L, multiply by 0.331) at screening had a mixed-meal
tolerance test performed at baseline and 26 weeks. Insulin
use was determined by downloading the insulin pump
(for pump users) at each visit or by reviewing the log of
insulin injections (kept by injection users) for 1 week before
each visit.
All adverse events were reported regardless of whether
the event was considered treatment-related and coded using
the Medical Dictionary for Regulatory Activities. Reportable
severe hypoglycemia was defined as an event characterized
by low blood glucose that required assistance of another per-
son to actively administer carbohydrate, glucagon, or other
resuscitative actions to treat altered consciousness. The
occurrence of diabetic ketoacidosis was defined by criteria
from the Diabetes Control and Complications Trial.16 Serum
lactate was not routinely measured and was assessed only if
deemed clinically indicated.
Outcomes
Primary Outcome
The primary efficacy outcome was the change in HbA1c level
(assessed at the central laboratory) frombaseline to 26weeks.
Prespecified secondary HbA1c outcomes (HbA1c <7.5%, abso-
lute decrease by ≥0.5%, and absolute increase by ≥0.5%) also
were assessed.
Other Secondary and Exploratory Outcomes
Prespecified secondary and exploratory outcomes included
continuous glucose monitor indices; total daily insulin per kg
of body weight; total basal insulin per kg of body weight; BMI
percentiles (analysis using z score also performed) adjusted
for age and sex15; waist circumference; body composition
measured by DXA; blood pressure percentiles adjusted for
age, sex, and height (calculated using CDC reference tables);
serum lipid levels; adipocytokines; inflammatory markers;
and C-peptide levels. Posthoc binary variables were analyzed
for total daily insulin, BMI, and weight change.
Safety Outcomes
All reported adverse events were tabulated. The primary
safety outcomes included gastrointestinal events, occur-
rences of lactic acidosis, severe hypoglycemia, and diabetic
ketoacidosis. Changes in serum creatinine and liver
enzymes also were assessed.
Statistical Analysis
A sample size of 136 participants was planned to have 90%
power to detect a difference in change in HbA1c between
treatment groups and assuming a population difference of
0.5%, standard deviation of 26-week values of 1.0%, corre-
lation between baseline and 26-week values of 0.56, type I
error rate of 5% (2-sided), and no more than a 15% loss
to follow-up.
Analyses followed the intent-to-treat principle. Partici-
pantswhodiscontinueduseof the studydrug remained in the
study to complete follow-up and were analyzed according to
the randomized treatment assignment.
Treatment group comparisons for continuous outcomes
were conductedusing a linearmixedmodel adjusted for base-
line level of the outcome variable and random center effects.
Treatment group differences in binary outcomeswere evalu-
ated in logistic regression models adjusted for baseline level
of the outcome variable.
The proportions of participants experiencing any ad-
verse event, any related adverse event, any gastrointestinal
event, any event other than a gastrointestinal event, at least 1
severe hypoglycemic event, and at least 1 diabetic ketoacido-
sis event in each treatment group were compared using the
Fisher exact test. The number of adverse events, new ad-
verse events, serious adverse events, andnonserious adverse
eventswere comparedbetweengroupsusing aWilcoxon rank
sum test.
Analyses were conducted using SAS version 9.4 (SAS
Institute). A 95% CI was reported with each mean value. All
P values were 2-sided. The primary analysis test of signifi-
cance was conducted with a threshold of .05. P values for
secondary analyses were unadjusted for multiple compari-
sons and should be considered exploratory. The Rubin
method was used to impute missing HbA1c data for the pri-
mary analysis.17 Analyses of secondary outcomes were per-
formed for the available measurements (without imputation
for missing data). Analyses were performed on all efficacy
outcomes obtained at 13 weeks by methods similar to those
used at 26 weeks. Sensitivity analyses adjusting for potential
confounders and including only eligible participants who
were taking at least 1500mg of the study drug at the 26-week
visit (per-protocol analysis) were performed.
Results
Between October 2013 and February 2014, 140 participants
were randomized to the metformin (n = 71) or placebo
(n = 69) group (Figure). The mean (SD) age of participants
was 15.3 (1.7) years (range, 12.1 to 19.6 years); 92 participants
(66%) were female and 103 (74%) were white. Mean HbA1c
was 8.8% (0.7%), mean BMI z score was 1.6 (0.3), and mean
total daily insulin was 1.1 (0.2) U/kg per day. Table 1 lists base-
line characteristics according to treatment group.
Visit Completion
The 26-week primary outcome visit was completed by 70 of
71 (99%) participants in the metformin group and by all 69
(100%) participants in the placebo group (Figure and eFigure
1 in Supplement 2). Telephone call and other visit completion
rates were similar between treatment groups (eFigure 1 in
Supplement 2).
Treatment
Five participants (7%) in the metformin group and 4 (6%)
in the placebo group discontinued treatment prior to the
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26-week follow-up. Of these, 3 participants (4%) in the met-
formin group discontinued the drug because of an adverse
event (0 in the placebo group). At 13 weeks, 60 participants
(84%) in the metformin group and 66 (96%) in the placebo
group reported taking 2000 mg/d; at 26 weeks, 57 partici-
pants (80%) in the metformin group and 65 (94%) in the pla-
cebo group reported taking 2000 mg/d. Based on pill counts
and the expected dose, mean (SD) medication adherence
over the 26 weeks was 83% (24%) in the metformin group
and 88% (23%) in the placebo group, and the mean of each
participant’s mean daily dose was 1699 (358) mg in the met-
formin group and 1793 (283) mg, in the placebo group
(eTable 2 in Supplement 2).
Efficacy Analyses
Glycemic Control
Baseline HbA1c was 8.8% (0.7%) in each group. At 13 weeks,
mean change in HbA1c from baseline was −0.2% in the met-
formin group and0.1% in the placebo group (meandifference
adjusted forbaseline,−0.3%[95%CI,−0.6%to0.0%];P = .02).
However, thisdifferencewasnot sustainedat the26-weekpri-
mary outcome visit in which the mean change in HbA1c from
baselinewas0.2%in themetformingroupand0.2%in thepla-
cebo group (mean adjusted difference, 0.0% [95% CI, −0.3%
to0.3%];P = .92) (eFigure2 inSupplement2).OtherHbA1cout-
comes are shown in Table 2. The sensitivity analyses showed
no significant treatment group differences for the change in
HbA1c at 26weeks (eTable 3 inSupplement2). Continuousglu-
cosemonitoring outcomes showed no significant differences
(eTable 4 in Supplement 2).
Total Daily Insulin
At 26weeks,mean total daily insulin dose per kgwas lower in
themetformingroup(−0.1U/kgperday)vs in theplacebogroup
(0.0U/kgperday;meandifference,−0.1 [95%CI,−0.2 to−0.0];
P < .001;Table3); 16participants (23%) in themetformingroup
vs 1 (1%) in the placebo grouphad a reduction in total daily in-
sulin of 25% or greater from baseline to 26 weeks (mean dif-
ference, 21% [95% CI, 11% to 32%]; P = .003).
Measures of Adiposity
From baseline to 26 weeks, less weight gain occurred in the
metformin group (0 kg) compared with the placebo group
(2 kg; mean difference, −2 [95% CI, −3 to −1]; P = .003;
Table 3). More participants in the metformin group (12 [17%])
than in the placebo group (5 [7%]) had a reduction in body
weight of at least 5% from baseline to 26 weeks (mean differ-
ence, 10% [95% CI, −1% to 21%]; P = .09). An increase in
weight of more than 5% from baseline to 26 weeks was expe-
rienced by 17 participants (24%) in the metformin group vs
28 (41%) in the placebo group (mean difference, −16% [95%
CI, −32% to −1%]; P = .04). There also was a greater reduction
from baseline in BMI z score in the metformin group
(0.0 [95% CI, −0.1 to 0.0]) vs the placebo group (0.1 [95% CI,
Figure. Flow of Study Participants: Metformin for AdolescentsWith Type 1 Diabetes
23 Excluded
5 HbA1c was >10% at screening
1 BMI was <85th percentile at
screening visit
1 Uncontrolled celiac disease
2 Taking excluded medication
1 Switched insulin modality between
screening and randomization visit
3 Declined participation after consent
3 HbA1c was <7.5% at screening
7 Total daily insulin was <0.8 units/kg
140 Randomized
71 Randomized to receive metformin
intervention
71 Received intervention as
randomized
163 Patients enrolled then screened
71 Included in analysis
1 Participant lost to follow-up
(26-wk data imputed from 
13-wk visit)
1 Lost to follow-up (withdrew at
patient request)
5 Discontinued intervention
3 Adverse event
2 Participant nonadherent with
taking drug but agreed to
remain in study
69 Randomized to receive placebo
69 Received placebo as randomized
69 Included in analysis
0 Lost to follow-up
4 Discontinued intervention
(participant nonadherent with
taking drug but agreed to remain
in study)
HbA1c indicates hemoglobin A1c;
BMI, bodymass index.
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Table 1. Baseline Characteristics
Metformin
(n = 71)
Placebo
(n = 69)
Female sex, No. (%) 44 (62) 48 (70)
Age, mean (SD), y 15.4 (1.7) 15.1 (1.8)
12-15 y, No. (%) 43 (61) 47 (68)
16-19 y, No. (%) 28 (39) 22 (32)
Race/ethnicity, No. (%)
White 51 (72) 52 (75)
Black 4 (6) 5 (7)
Hispanic or Latino 13 (18) 11 (16)
Asian 2 (3) 0
Biracial or multiracial 1 (<1) 1 (<1)
Duration of diabetes, mean (SD), y 7.5 (3.6) 6.4 (3.0)
Duration by age group, No. (%)
1-2 y 5 (7) 9 (13)
3-5 y 23 (32) 25 (36)
6-8 y 19 (27) 22 (32)
≥9 y 24 (34) 13 (19)
BMIa
Z score, mean (SD) 1.6 (0.4) 1.7 (0.3)
Percentile, mean (SD)b 93.7 (4.1) 94.3 (3.8)
Overweight, 85th-<95th percentile, No. (%) 36 (51) 26 (38)
Obese, ≥95th percentile, No. (%) 33 (46) 41 (59)
Tanner staging, No. (%)c
Pubic hair
Stage 1 1 (<1) 1 (<1)
Stage 2 1 (<1) 3 (4)
Stage 3 5 (7) 7 (10)
Stage 4 16 (23) 9 (13)
Stage 5 48 (68) 49 (71)
Breasts or genitals
Stage 1 1 (<1) 1 (<1)
Stage 2 0 2 (3)
Stage 3 5 (7) 6 (9)
Stage 4 12 (17) 9 (13)
Stage 5 53 (75) 51 (74)
Highest parental education level, No. (%)
≤High school diploma or GED 22 (31) 20 (29)
Associate’s degree 10 (14) 12 (17)
Bachelor’s degree 18 (25) 15 (22)
Master’s degree 12 (17) 13 (19)
Professional 5 (7) 7 (10)
Unknown or unanswered 4 (6) 2 (3)
Annual household income, No. (%), $
<35 000 5 (7) 7 (10)
35 000 to <50 000 3 (4) 7 (10)
50 000 to <75 000 10 (14) 13 (19)
75 000 to <100 000 11 (15) 6 (9)
100 000 to <200 000 14 (20) 12 (17)
≥200 000 5 (7) 6 (9)
Unknown or unanswered 23 (32) 18 (26)
Insurance, No. (%)
Private 53 (75) 48 (70)
Other 14 (20) 15 (22)
None 0 2 (3)
Unknown or unanswered 4 (6) 4 (6)
(continued)
Table 1. Baseline Characteristics (continued)
Metformin
(n = 71)
Placebo
(n = 69)
Severe hypoglycemia episodes/events since
diagnosis of type 1 diabetes, No. (%)d
None 52 (73) 52 (75)
1-2 14 (20) 10 (14)
3-4 3 (4) 2 (3)
≥5 2 (3) 5 (7)
Diabetic ketoacidosis episodes/events since
diagnosis of type 1 diabetes, No. (%)e
None 53 (75) 48 (70)
1-2 15 (21) 13 (19)
3-4 2 (3) 6 (9)
≥5 1 (<1) 2 (3)
HbA1c level, mean (SD), % of total hemoglobin 8.8 (0.8) 8.8 (0.7)
HbA1c, No. (%), grouped by level
<8.5% 25 (35) 24 (35)
8.5%-9.4% 32 (45) 26 (38)
≥9.5% 14 (20) 19 (28)
Sensor glucose, mean (SD), mg/dL 206 (35) 208 (34)
Insulin pump use, No. (%) 50 (70) 49 (71)
Continuous glucose monitor use, No. (%) 2 (3) 2 (3)
Self-monitoring of blood glucose/d,
mean (SD)f
4.5 (1.2) 4.6 (1.6)
Self-monitoring blood glucose group,
No. (%)
3 13 (18) 14 (20)
4-5 44 (62) 43 (62)
≥6 14 (20) 12 (17)
Total daily insulin, mean (SD), U/kg per d 1.1 (0.2) 1.1 (0.2)
Total daily insulin, No. (%), grouped by level
<1.0 33 (46) 26 (38)
1.0-1.4 33 (46) 39 (57)
≥1.5 5 (7) 4 (6)
Total basal/long-acting insulin,
mean (SD), U/kg per d
0.5 (0.1) 0.5 (0.1)
Abbreviations: BMI, bodymass index; GED, General Educational Development.
SI conversion factor: to convert glucose frommg/dL tommol/L, multiply by
0.0555.
a Calculated from height and weight and adjusted for age and sex using growth
chart tables from the Centers for Disease Control and Prevention.
b Two participants in themetformin group and 2 in the placebo groupmet the
criteria for BMI (>85th percentile) at the screening visit that changed
(<85th percentile) at the baseline/randomization visit.
c For pubic hair: stage 1, none; 2, initial hair is straight and fine; 3, curly, coarse,
and dark; 4, like adult hair but limited in area; 5, adult distribution with spread
tomedial thighs. For female breasts: stage 1, none; 2, breast buds begin;
3, breasts and areolas grow; 4, nipples and areolas form separate mound
protruding from breast; 5, areola rejoins breast contour. Male genitalia: stage 1
is preadolescent—testes, scrotum, and penis are approximately the same size
and proportion as in early childhood; 2, scrotum and testes have enlarged and
skin is changed in texture with reddening of scrotal skin; 3, initial growth of
penis in length and breadth with further growth of the testes and scrotum;
4, further enlargement of the penis, testes, and scrotum, development of the
glans, and the scrotal skin has further darkened; 5, genitalia are adult with
regard to size and shape.
dDefined as cognitive impairment that required assistance to treat.
e Excludes diabetic ketoacidosis at diagnosis.
f Obtained from download of study-providedmeter.
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0.0 to 0.1]) at 26 weeks (mean difference, −0.1 [95% CI, −0.2
to −0.1]; P < .001; Table 3); 17 participants (24%) in the met-
formin group and 5 (7%) in the placebo group had a BMI
reduction at least 10% from baseline to 26 weeks (mean dif-
ference, 17% [95% CI, 5% to 29%]; P = .01).
Mean change from baseline to 26 weeks in DXA-
measured total mass was 0 kg (95% CI, −1 to 1) in the metfor-
min group vs 2 kg (95% CI, 1 to 3) in the placebo group (mean
difference, −2 [95%CI, −4 to−1];P < .001;Table 3), andchange
in%of body fat was 0% (95%CI, −1% to 1%) in themetformin
group vs 1% (95% CI, 0% to 1%) in the placebo group (mean
difference, −1% [95%CI, −2% to0%];P = .04). Therewas a re-
duction inDXA-measured total fat kg (mean difference, −2 kg
[95% CI, −3 to −1]; P < .001) in the metformin group com-
pared with the placebo group.
Other Exploratory Outcomes
No significant differences between groups were observed in
change in blood pressure percentiles or lipid levels (Table 3)
or inflammatory markers, C-reactive protein, or C peptide
(eTable 5 in Supplement 2).
Safety Analyses
At least 1 adverse event was reported for 57 (80%) of the 71
participants in the metformin group and 39 (57%) of the 69
participants in the placebo group (mean difference, 24%
[95% CI, 7% to 39%]; P = .003; Table 4). Gastrointestinal
events were the most frequent type of adverse event with 50
events in the metformin group (70% [95% CI, 60% to 81%])
and 24 events in the placebo group (35% [95% CI, 23% to
46%]; P < .001; Table 4) (mean difference, 36% [95% CI, 19%
to 51%]; P < .001). Excluding gastrointestinal events, at least 1
other adverse event was reported by 7 participants (10%) in
the metformin group (95% CI, 3% to 17%) vs 15 (22%) in the
placebo group (95% CI, 12% to 32%) (mean difference, −12%
[95% CI, −28% to 4%]; P = .06). However, no system organ
class other than gastrointestinal showed a significant treat-
ment group difference. Lactic acidosis was not reported for
any participant. There were no significant increases in serum
creatinine or liver enzyme levels.
Diabetic ketoacidosis occurred in 3 (4% [95% CI, 1% to
9%]) participants in the metformin group vs 2 (3% [95% CI,
1% to 7%]) participants in the placebo group (mean differ-
ence, 1% [95% CI, −16% to 18%]; P ≥ .99). Severe hypoglyce-
mia occurred in 5 (7% [95% CI, 1% to 13%]) participants in the
metformin group and 0 in the placebo group (mean differ-
ence, 7% [95% CI, −9% to 23%]; P = .06). At 6 months, using
blinded continuous glucose monitoring, mean (SD) time of
less than 70 mg/dL was 5% (6%) in the metformin group vs
6% (8%) in the placebo group (mean difference, 0.0%, [95%
CI, 0.0% to 0.0%]; P = .76).
Discussion
This multicenter placebo-controlled study of overweight
and obese adolescents with type 1 diabetes failed to show a
sustained effect of metformin as an adjunct to basal-bolus
Table 2. Hemoglobin A1c Outcomes
Metformin
(n = 71)
Placebo
(n = 69)
Mean Difference
(95% CI) P Valuea
Baseline
HbA1c, mean %
(95% CI)
8.8 (8.6 to 9.0) 8.8 (8.6 to 9.0)
13 Weeksb
HbA1c, mean %
(95% CI)
8.7 (8.4 to 8.9) 8.9 (8.6 to 9.1)
Change from
baseline to 13
weeks, mean %
(95% CI)
−0.2 (−0.4 to 0.0) 0.1 (−0.1 to 0.3) −0.3 (−0.6 to 0.0) .02
HbA1c, No. (%)
[95% CI]
Decrease ≥0.5% 20 (29) [18 to 41] 20 (29) [18 to 41] 0 (−17 to 17) .94
Increase ≥0.5% 12 (18) [8 to 27] 19 (28) [17 to 39] −10 (−27 to 7) .13
<7.5% 7 (10) [3 to 18] 0 10 (−7 to 27) .01
26 Weeksb
HbA1c, mean %
(95% CI)
9.0 (8.8 to 9.2) 8.9 (8.7 to 9.2)
Change from
baseline to 26
weeks, mean %
(95% CI)
0.2 (0.0 to 0.4) 0.2 (−0.1 to 0.4) 0.0 (−0.3 to 0.3) .92
HbA1c, No. (%)
[95% CI]
Decrease ≥0.5% 13 (19) [8 to 28] 18 (26) [15 to 37] −8 (−24 to 9) .22
Increase ≥0.5% 31 (44) [32 to 56] 24 (35) [23 to 46] 10 (−7 to 26) .22
<7.5% 2 (3) [<1 to 7] 3 (4) [<1 to 9] −1 (−18 to 15) .68
Abbreviation: HbA1c, hemoglobin A1c.
a P values for change in HbA1c were
obtained from linear mixedmodels
adjusted for baseline HbA1c and
random center effects. P values for
binary outcomes were obtained
from logistic regressionmodels
adjusted for baseline HbA1c and
random center effects.
bHbA1c values for 4 participants
missing a level at 13 weeks and for 1
participant missing a level at 26
weeks were imputed using the
Rubin method of multiple
imputation.
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insulin therapy on glycemic control after 26 weeks. Despite
a small decrease in HbA1c favoring the metformin group at
13 weeks, mean HbA1c levels increased by ≈ 0.2% from base-
line values of 8.8% in each treatment group at 26 weeks.
There also were no statistically or clinically significant dif-
ferences from baseline to 26 weeks in continuous glucose
monitor glucose profiles between treatment groups. The
lack of benefit on glycemic control at 6 months is unlikely
from bias because study completion was nearly 100%, the
treatment discontinuation rate was low, and blinding of
treatment assignment was maintained. It does not seem
likely that different glycemic control results would have
been achieved with a longer treatment period.
Although a benefit at 6 months on glycemic control was
not observed, in hypothesis-generating analyses, metformin
compared with placebo was associated with reductions in
weight gain, BMI, body fat, and total daily insulin dose. The
clinical relevance of these treatment group differences is un-
certain. Other studies also have shown a decrease in BMI and
total daily insulin dose with metformin.10,12
Although the changes in body weight composition and
insulin requirements may have improved insulin sensitivity,
there were no concomitant improvements in cardiovascular
risk factors. Metformin treatment failed to improve a num-
ber of clinical and biochemical risk factors for future cardio-
vascular disease including blood pressure, plasma lipid con-
centrations, and adipocytokines. However, the 6-month
study period may have been too short to show beneficial
effects on these surrogate markers of future cardiovascular
disease. In this regard, it is noteworthy that in the study of
Lund et al,18,19 metformin treatment in adults with type 1
diabetes lowered total and LDL-C after 1 year.
Metformin generally was well-tolerated, although the
frequency of gastrointestinal adverse effects was greater
than with placebo. Severe hypoglycemia occurred in 5 par-
ticipants in the metformin group and did not occur in any
participant in the placebo group. In 4 of the 5 of the partici-
pants who experienced severe hypoglycemia, the event
occurred within the first 6 weeks of starting metformin
(when the insulin dose was still being adjusted). This is
noteworthy and suggests careful monitoring during the first
few weeks following initiation of any noninsulin drug pre-
scribed for glycemic control. There were no episodes of lac-
tic acidosis, which is consistent with other reports of met-
formin use in the pediatric population.10
The primary limitation in interpretation of the results is
uncertainty as to whether a more standardized approach to
insulin management could have produced different results.
Table 4. Safety Outcomes
Metformin
(n = 71)
Placebo
(n = 69) P Valuea
No. of adverse eventsb 184 78
No. per participantb
Mean (SD) 3 (2) 2 (2)
.005
Median (IQR) 3 (2-5) 2 (1-3)
No. of serious adverse eventsc 3 3
No. per participantc
Mean (SD) 0 (0) 0 (0)
.66
Median (IQR) 0 (0-0) 0 (0-0)
No. of nonserious adverse events 181 75
No. per participant
Mean (SD) 3 (2) 2 (2)
.002
Median (range) 3 (1-8) 2 (1-3)
Participants with adverse events,
No. (%) [95% CI]
≥1 Adverse event 57 (80) [71-90] 39 (57) [45-69] .003
≥1 Related adverse eventd 46 (65) [53-76] <.001
≥1 Gastrointestinal adverse event 50 (70) [60-81] 24 (35) [23-46] <.001
≥1 Adverse event other than
gastrointestinal events
7 (10) [3-17] 15 (22) [12-32] .06
≥1 Diabetic ketoacidosis event 3 (4) [<1-9] 2 (3) [<1-7] >.99
≥1 Severe hypoglycemic event 5 (7) [1-13] 0 .06
Biochemical hypoglycemia
at 6 monthse
Percentage of time <70 mg/dL
Mean (SD) 5 (6) 6 (8)
.76
Median (IQR) 2 (1-8) 4 (1-7)
Percentage of time <50 mg/dL
Mean (SD) 2 (4) 2 (5)
.51
Median (IQR) 0 (0-2) 0 (0-1)
Abbreviation: IQR, interquartile
range.
a P values were calculated using the
Wilcoxon rank sum test for
continuous safety outcomes and
the Fisher exact test for binary
outcomes unless otherwise
specified.
bAdverse events from the same
system class or underlying condition
that occurred within 7 days were
counted as the same event.
c All serious adverse events were for
diabetic ketoacidosis except for 1
hospitalization for a suicide attempt
in the placebo group.
dRelated adverse events are any
event thought by the investigator to
be associated with the study drug.
e Biochemical hypoglycemia was
measured with blinded continuous
glucosemonitor. A ranked
transformation for the change in the
outcomemeasure was used in a
linear mixedmodel adjusted for the
rank transformation of the baseline
outcomemeasure and random
center effect.
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Because changes in the insulin regimen in this study were
left to the discretion of treating clinicians, it is difficult to
determine to what extent the greater reductions in total
daily insulin doses in metformin-treated participants
affected our ability to show treatment-group differences in
changes in HbA1c levels. This difficulty is compounded by
the fact that there are so many other factors that affect the
changes in HbA1c levels—especially in adolescents. Another
limitation is that adherence was measured by pill counts,
which may or may not have been accurate.
Conclusions
Amongoverweight adolescentswith type 1diabetes, the addi-
tion ofmetformin to insulin did not improve glycemic control
after 6 months. Of multiple secondary end points, findings
favoredmetformin only for insulin dose andmeasures of adi-
posity; conversely,metformin resulted in an increased risk for
gastrointestinaladverseevents.Theseresultsdonotsupportpre-
scribingmetformintoadolescents to improveglycemiccontrol.
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